Buka Investments Limited Overview
Buka Investments Limited is a dormant former listed shell. For about fifteen years it was the listed parent of a South African beauty and wellness franchisor whose brands were Placecol Skin Care Clinics, Dream Nails Beauty Salons and Perfect 10 Nail and Body Studios. It also owned the Placecol skin care product range.
The operating group lost revenue for years, falling from R101.1m in FY2016 to R19.0m by FY2022. COVID-19 then forced a restructuring. An Absa Bank COVID-19 loan required the operating subsidiary to sit outside a JSE-listed group, so management sold every subsidiary to the related-party i-BLOOM group for R7.63m. A new controlling shareholder, B&B Media, took 61.26% of the empty listed vehicle.
B&B Media renamed the company Buka Investments and planned a reverse takeover into fashion footwear (Socrati Footwear and Caralli Leather Works). That deal was shelved in February 2023. The JSE suspended the shell and later removed its listing on 4 September 2024. Today Buka is an unlisted company with negligible net assets and no disclosed operations.
The company's own description (paraphrased from its latest operating-era filings)
In its FY2020 results (year ended 29 February 2020), Imbalie Beauty described itself as a beauty and wellness solutions group. It said its primary focus was developing, growing and innovating its own skin care product brands and treatments, delivered through a franchise salon footprint of three chains: Placecol Skin Care Clinics, Perfect 10 and Dream Nails Beauty Salons. It said its skin care brands reached consumers through its own salon footprint, large retail groups, pharmacies, independent salons and online platforms. (Source: Imbalie Beauty reviewed provisional results FY2020, 7 Aug 2020.)
After the disposal, Buka's FY2023 audited results (31 May 2023) describe the company as a listed shell on the JSE. They say it intended to acquire "earmarked fashion businesses", subject to board, shareholder and JSE approval. Profile ShareData's company summary describes Buka's intended model as a house of brands: retailers of exclusive shoes and accessories sourced internationally and locally, with the Socrati and Caralli acquisitions pending. Those acquisitions never completed.
Independent characterisation
Phase 1: operating beauty franchisor (2007 – January 2022). The business model was a hybrid of three things:
-
A franchisor, earning royalties and fees from franchised salons. The group had more than 150 salons nationally in FY2016 and January 2018.
-
A brand owner and distributor of its own skin care brands (Placecol, Skinderm) and of third-party professional brands. Products were sold into the salon network, retailers (including in-store beauty outlets in Edcon stores) and pharmacies.
-
A training provider through the Imbalie Beauty Training Academy, later the Imbalie Beauty Wellness Academy and the i-BLOOM Beauty & Wellness Academy.
The group also owned corporate salons until FY2017, when it decided to close them. Until 2020 it held head leases on behalf of franchisees, which created contingent liabilities.
Phase 2: cash shell (February 2022 – September 2024). From February 2022 the listed company held only cash, receivables and a deferred tax asset. It had no revenue. Its expenses were mainly JSE, sponsor, audit, legal and directors' fees.
Phase 3: unlisted dormant entity (September 2024 – present). No public information was found on its activities, assets or any later transaction.
Revenue model mix (operating era)
| Revenue stream | Description | Disclosed split |
|---|---|---|
| Product sales (own brands) | Placecol and Skinderm skin care sold to salons, retailers and pharmacies | — |
| Product sales (third-party brands) | Imported international professional brands | Not publicly disclosed. Management said it deliberately shifted toward own brands in FY2020–FY2022 to lift gross margin |
| Franchise royalties and fees | Royalties from franchised salons | Not publicly disclosed. Royalties received from the related-party Beauty Flagship salons were R1.197m (FY2019), R540k (FY2020) and R1.21m (FY2022) |
| Training | Academy courses (34 courses offered in FY2017) | — |
| Rental income | Property (Imbalie Innovation) let to related parties such as Amka Products | R90k (FY2020), R152k (FY2021), R114k (FY2022) to Amka Products |
The group never reported by segment. It stated that it was managed as one operating unit (IFRS 8 disclosure, FY2020–FY2023).
Value chain position, customers and end-markets
Value chain: A brand owner and franchisor in the middle of the professional beauty value chain. Manufacturing appears to have been outsourced (the FY2020 results reference brand development but no factories). Distribution was outsourced in FY2017 (BusinessDay, 2 Jun 2017).
Customer types: Franchisees, independent salons, large retail groups such as Edcon, pharmacy groups (a pharmacy group ordered Placecol for 93 new outlets on 26 March 2020), and end consumers through online channels and the Customer Solutions Division launched 3 August 2020.
End-markets: Professional salon treatments and retail skin care in South Africa, with some cross-border sales in Southern Africa (BusinessDay, 31 Jan 2018; FY2020 IFRS 8 note).
Strategy
Stated strategy, by era (paraphrased)
| Era | Stated strategic themes | Source |
|---|---|---|
| FY2017–FY2020 (Imbalie) | Turnaround: close corporate salons, outsource distribution, build a training academy, focus on own brands for margin, grow pharmacy and retail distribution, open "more successful" franchised salons. The vision was to be the leading and most desirable beauty and wellness solutions group nationally and internationally | BusinessDay 2 Jun 2017; FY2020 results |
| FY2021 (COVID) | Survival and repositioning: Customer Solutions Division, digitising the academy, R7m rights offer (not implemented), sale of the property company to settle debt | FY2020 results |
| FY2022 (disposal) | Comply with the Absa loan condition by moving operations into an unlisted entity (i-BLOOM), citing substantial cost savings outside the JSE | FY2022 results; Business Report 7 Jul 2021 |
| FY2023 onward (Buka) | Reposition and rebrand into the fashion industry by reversing "earmarked fashion businesses" into the listed shell, with the stated aim of creating substantial shareholder value. The board said it was confident the major shareholder's business acumen combined with the listing would build a sizable listed fashion business | FY2022 results; FY2023 results; interim Aug 2023 |
Initiative register (last 24 months of public disclosure: Sep 2022 – Sep 2024)
| Initiative | Date | Status | Source |
|---|---|---|---|
| Socrati Footwear / Caralli Leather Works reverse takeover (share-for-share, treated as a new listing) | Heads of Agreement 14–15 Jul 2022 | JSE extension to 31 Dec 2022 for the circular. Put on hold 24 Feb 2023 | Interim Aug 2022; FY2023 results |
| Revised reverse-takeover strategy "in conjunction with advisors" | Announced 29 Sep 2023, with a final transaction expected within about four months | Never announced. Listing removed 4 Sep 2024 | Interim Aug 2023 |
| Cost programmes | None disclosed. Costs rose 178% in FY2023 because of audit, legal, JSE and directors' fees | — | FY2023 results |
| ESG / sustainability commitments | None disclosed for Buka. Profile ShareData's summary describes the target fashion house as built around sustainability and community upliftment | — | Profile ShareData |
Medium-term targets and guidance
None were ever published. The only forward-looking quantitative statement is the FY2024 trading statement (loss per share of 17.00–20.00c).
Products & Services
All of the portfolio below belonged to the pre-2022 operating group and now sits outside Buka. Buka itself has no products or services.
Franchise salon chains
| Brand | Description | Target customer | Year / status | Pricing model | Source |
|---|---|---|---|---|---|
| Placecol Skin Care Clinics | Franchised skin care clinics offering facial and body treatments built around Placecol products. Repeatedly recognised by "Best of Bloemfontein", including a fifth consecutive year in 2019 | Mid-market female consumers who want professional skin care | Part of the original Placecol business; now i-BLOOM | Franchise royalties and fees (rates not disclosed) | FY2020 results; interim Aug 2019 |
| Dream Nails Beauty Salons | Franchised nail and beauty salons | Mass-market nail and beauty consumers | Acquired 2007 at listing; now i-BLOOM | Franchise royalties (not disclosed) | FY2022 results |
| Perfect 10 Nail and Body Studios | Franchised nail and body studios | Mass-market nail and beauty consumers | Acquired from A&V Beauty Products, effective 1 Mar 2012; now i-BLOOM | Franchise royalties (not disclosed) | Skinwell SENS 6 Mar 2012 |
| i-BLOOM by Placecol Skin, Hair & Beauty | New salon format. The first store opened at Chartwell Corner, Fourways, in Jan 2022 | Premium all-in-one beauty consumer | Launched Jan 2022, at the time of the disposal; never part of Buka | — | Team France Export / Professional Beauty |
| Corporate (company-owned) salons | Group-operated salons | — | Closure decided in FY2017 with a R9.9m impairment | — | BusinessDay, 2 Jun 2017 |
Footprint: more than 150 salons nationally in FY2016 and January 2018 (SENS 31 May 2016; BusinessDay 31 Jan 2018). FY2020 refers to closures of unprofitable salons. Group head leases held for franchisees fell from 28 in 2019 to 7 by July 2020 (FY2020 results).
Own skin care brands
| Brand / range | Description | Channels | Launch / latest | Source |
|---|---|---|---|---|
| Placecol (core range) | South African professional and retail skin care brand, about 40 years old in 2020. Its trademarks were revalued in FY2020, reversing an earlier impairment of R1.46m | Salons, retail groups, pharmacies, online | c.1980; trademark carrying value restored in FY2020 | FY2020 results; Profile Stock Exchange Handbook 2021 |
| Placecol Excellence | Range positioned around skin care at a biological level. Won a Pharmaceutical and Cosmetic Review award in Oct 2019 | Salons, pharmacies | Launched Jun 2019 | FY2020 results |
| Skinderm | Own skin care brand named in company descriptions | Salons, retail | Launch year not disclosed | GuruFocus business description (aggregator) |
| Brand | Role | Source |
|---|---|---|
| Beauté Pacifique | Imported professional skin care distributed by the group | Simply Wall St / Yahoo Finance profile |
| Bioeffect | Imported skin care distributed by the group | Simply Wall St / Yahoo Finance profile |
| Bodyography | Cosmetics distributed by the group (spelled "Bodyograpgy" in the aggregator text) | Simply Wall St / Yahoo Finance profile |
| "Scinderm" | Appears in aggregator text and may be a duplicate or misspelling of Skinderm | Simply Wall St / Yahoo Finance profile |
Services and other offerings
| Offering | Description | Launch | Source |
|---|---|---|---|
| Imbalie Beauty Training Academy / Wellness Academy | Beauty and wellness training. Offered 34 courses at launch in FY2017; trained the salon network in COVID protocols in 2020 | FY2017 | BusinessDay, 2 Jun 2017; FY2020 results |
| i-BLOOM Beauty & Wellness Academy | Online international training and education platform for beauty professionals | Oct 2020 | Team France Export; Ghost Mail |
| Customer Solutions Division | Direct-to-consumer sales of salon-quality home-use products, plus training therapists for home-based services | 3 Aug 2020 | FY2020 results; Ghost Mail |
| i-BLOOM magazine | Consumer magazine about skin, hair and beauty solutions | Sep 2020 | Team France Export |
| Edcon in-store beauty outlets | Beauty stores inside some Edcon outlets | Agreement announced Jan 2018 | BusinessDay, 31 Jan 2018 |
Planned (never completed) Buka portfolio
| Target | Description | Status | Source |
|---|---|---|---|
| Socrati Footwear (Pty) Ltd | Established South African retailer of women's and men's shoes | Heads of Agreement 14–15 Jul 2022. Put on hold 24 Feb 2023. Never completed | Interim Aug 2022; FY2023 results; Profile ShareData |
| Caralli Leather Works (Pty) Ltd | Men's leather shoe manufacturer | As above | As above |
| Eddels Shoes (Pty) Ltd | Shoe manufacturer in Pietermaritzburg, acquired by B&B Media (not Buka) in Feb 2023 | Not a Buka asset | FY2023 results |
Financial Narrative
Basis of preparation and comparability warnings
-
Five audited years used: FY2019 to FY2023. FY2024 (year ended 29 Feb 2024) audited results were due in the first week of July 2024, according to the 27 Jun 2024 trading statement. They could not be retrieved; the JSE PDF repository blocked access. Only the trading-statement range is available.
-
FY2021 and FY2022 operating figures come from the discontinued-operations note in the FY2022 audited results.
-
All per-share figures are restated for the 1:100 consolidation of 6 July 2022. For FY2019–FY2021 the restatement is the reported cents × 100. For FY2022 and FY2023 the figures are the post-consolidation amounts as reported.
-
FY2022 includes a R22.428m IAS 27 loss on disposal of subsidiaries.
-
FY2022 operating revenue covers 11 months.
Income statement
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue incl. discontinued operations (ZAR K) | 41,809 | 33,578 | 19,046 | 19,004 | 0 |
Cost of sales (ZAR K) | 16,098 | 10,183 | 5,459 | 5,401 | 0 |
Gross profit (ZAR K) | 25,711 | 23,395 | 13,587 | 13,603 | 0 |
Other operating income (ZAR K) | 2,822 | 2,527 | 2,103 | 1,148 | 0 |
Total operating expenses incl. listing costs (ZAR K) | 29,921 | 24,043 | 19,590 | 15,353 | 3,124 |
Goodwill impairment (ZAR K) | 0 | 0 | 3,560 | 0 | 0 |
EBIT excl. disposal loss (ZAR K) | -2,671 | 377 | -7,460 | -602 | -3,124 |
Finance costs (ZAR K) | 2,397 | 1,935 | 1,433 | 1,238 | 0 |
Investment income (ZAR K) | 117 | 62 | 5 | 0 | 194 |
Loss on disposal of subsidiaries (ZAR K) | 0 | 0 | 0 | 22,428 | 0 |
Pre-tax profit/(loss) (ZAR K) | -4,951 | -1,496 | -8,888 | -24,268 | -2,930 |
Taxation credit/(charge) (ZAR K) | 1,655 | -674 | -483 | 906 | -947 |
Net loss attributable (ZAR K) | -3,296 | -2,170 | -9,371 | -23,362 | -3,877 |
Headline loss (ZAR K) | -3,295 | -3,728 | -5,869 | -1,022 | -3,877 |
Basic EPS consolidation-adjusted (ZAR cents) | -24 | -16 | -68 | -168.79 | -28.01 |
Headline EPS consolidation-adjusted (ZAR cents) | -24 | -27 | -42 | -7.39 | -28.01 |
Diluted EPS consolidation-adjusted (ZAR cents) | -24 | -16 | -68 | -168.79 | -28.01 |
Dividends per share (ZAR cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares post-consolidation (million) | 13.77 | 13.84 | 13.84 | 13.84 | 13.84 |
Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Gross margin (%) | 61.50 | 69.67 | 71.34 | 71.58 |
EBIT margin excl. disposal loss (%) | -6.39 | 1.12 | -39.17 | -3.17 |
Net margin (%) | -7.88 | -6.46 | -49.20 | -122.93 |
Operating expenses to revenue (%) | 71.57 | 71.60 | 102.86 | 80.79 |
Income Statement
| Metric | FY2015 | FY2016 | FY2017 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
Revenue (ZAR K) | 91,886 | 101,111 | 96,500 | 41,809 | 33,578 | 19,046 | 19,004 | 0 |
Income Statement (Half-Yearly)
| Metric | H1 FY2019 | H1 FY2020 | H1 FY2021 |
|---|---|---|---|
Six-month revenue to 31 Aug (ZAR K) | 22,410 | 18,375 | 7,646 |
Six-month loss before tax (ZAR K) | -2,550 | -384 | -3,690 |
Balance Sheet and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Total assets (ZAR K) | 72,204 | 67,319 | 61,207 | 7,079 | 3,521 |
Cash and equivalents gross (ZAR K) | 131 | 47 | 107 | 1 | 3,273 |
Bank overdraft (ZAR K) | 3,937 | 4,021 | 2,071 | 0 | 0 |
Total interest-bearing debt incl. overdraft and leases (ZAR K) | 19,327 | 18,932 | 23,417 | 0 | 0 |
Net debt (ZAR K) | 19,196 | 18,885 | 23,310 | -1 | -3,273 |
Goodwill and intangible assets (ZAR K) | 17,465 | 19,229 | 15,323 | 0 | 0 |
Deferred tax asset (ZAR K) | 23,985 | 22,975 | 22,536 | 947 | 0 |
Total liabilities (ZAR K) | 30,309 | 28,032 | 31,291 | 524 | 844 |
Total equity (ZAR K) | 41,895 | 39,287 | 29,916 | 6,554 | 2,677 |
Accumulated loss (ZAR K) | -72,871 | -75,041 | -84,412 | -107,179 | -111,055 |
Stated capital (ZAR K) | 113,732 | 113,732 | 113,732 | 113,732 | 113,732 |
NAV per share consolidation-adjusted (ZAR cents) | 303 | 284 | 216 | 47.35 | 19.34 |
Key Financials
| Metric | FY2019 | FY2020 |
|---|---|---|
Short-term debt incl. overdraft and leases (ZAR K) | 11,520 | 4,672 |
Long-term debt (ZAR K) | 7,807 | 143 |
Debt reclassified to disposal groups (ZAR K) | 0 | 14,117 |
Liquidity & Coverage Ratios
| Metric | FY2019 | FY2020 | FY2022 | FY2023 |
|---|---|---|---|---|
Working capital (ZAR K) | -7,888 | -3,916 | 5,607 | 2,677 |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Operating cash flow (ZAR K) | 253 | 1,121 | -3,108 | -518 | 3,272 |
Net investing cash flow (ZAR K) | 27 | 73 | 483 | 1,641 | 0 |
Net financing cash flow (ZAR K) | -124 | -1,362 | 4,635 | 842 | 0 |
Net change in cash (ZAR K) | 156 | -168 | 2,010 | 1,965 | 3,272 |
Closing cash net of overdraft (ZAR K) | -3,806 | -3,974 | -1,964 | 1 | 3,273 |
Dividends paid (ZAR K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (ZAR K) | 0 | 0 | 0 | 0 | 0 |
Proceeds from share issues (ZAR K) | 3,316 | 0 | 0 | 0 | 0 |
Cash Flow (FY2019–FY2020)
| Metric | FY2019 | FY2020 |
|---|---|---|
Capex incl. PPE and intangibles (ZAR K) | 27 | 638 |
Free cash flow (OCF less capex) (ZAR K) | 226 | 483 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
ROE on closing equity (%) | -7.87 | -5.52 | -31.32 | -356.45 | -144.83 |
ROA on closing assets (%) | -4.56 | -3.22 | -15.31 | -330.02 | -110.11 |
Debt to equity (x) | 0.46 | 0.48 | 0.78 | 0 | 0 |
Asset turnover on closing assets (x) | 0.58 | 0.50 | 0.31 | 2.68 | 0 |
Financial Ratios (x)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Interest coverage (x) | -1.11 | 0.19 | -5.21 | 1.28 |
Financial Ratios (x) (FY2019–FY2023)
| Metric | FY2019 | FY2020 | FY2022 | FY2023 |
|---|---|---|---|---|
Current ratio (x) | 0.64 | 0.72 | 11.70 | 4.17 |
Working Capital (Days)
| Metric | FY2019 | FY2020 |
|---|---|---|
Days inventory outstanding (days) | 133.8 | 197.5 |
Days sales outstanding (days) | 64.5 | 46.0 |
Days payables outstanding (days) | 232.7 | 326.2 |
Cash conversion cycle (days) | -34.4 | -82.7 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
South Africa incl. cross-border sales by SA companies (ZAR K) | 33,578 | 19,046 | 19,004 |
South Africa share of revenue (%) | 100 | 100 | 100 |
South Africa revenue growth YoY (%) | -19.7 | -43.3 | -0.2 |
Valuation Snapshot
| Metric | Value | As of | Source |
|---|---|---|---|
Last price (approx.) | R0.73 | Suspended price, carried to removal | GuruFocus; implied by Profile ShareData market cap |
Market capitalisation | R10.10m | 3 Sep 2024 | Profile ShareData |
Shares in issue | 13,840,392 | Since 6 Jul 2022 | FY2023 results |
1-year total return (CAGR) | 0.00% (no trading while suspended) | 17 Dec 2024 | iocharts (aggregator) |
3-year return (CAGR) | -96.68% | 17 Dec 2024 | iocharts (aggregator) |
5-year return (CAGR) | -87.04% | 17 Dec 2024 | iocharts (aggregator) |
10-year return (CAGR) | -69.83% | 17 Dec 2024 | iocharts (aggregator) |
Market Valuation
| Metric | Aug 2022 | Aug 2023 | Sep 2024 |
|---|---|---|---|
Market capitalisation (ZAR Mn) | 13.4 | 10.1 | 10.1 |
Valuation Multiples
| Multiple | Buka | Comment |
|---|---|---|
P/B vs FY2023 equity (R2.677m) | 3.8x | R10.1m ÷ R2.677m |
P/B vs Aug 2023 equity (R1.053m) | 9.6x | R10.1m ÷ R1.053m |
Enterprise value (Aug 2023) | About R8.7m | Market cap R10.1m less cash R1.41m; no debt |
Peer multiples | Not compiled | Not meaningful for a shell |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends paid in any year retrieved (FY2015–FY2023). Each set of results states that no dividend will be paid |
Dividend policy | Not formally articulated beyond the annual "no dividend" statements |
Buyback authorisations | None disclosed |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | No debt since Feb 2022. Before the disposal, debt was mostly short-term: R11.5m short-term vs R7.8m long-term in FY2019 |
Capital raisings | Three rights offers since the 2007 listing, the last in Jan 2018 (R3.3m raised against a R15m target). About R6m injected in connection with the 2022 control change |
Analyst consensus | None. No sell-side coverage identified |
Corporate actions | 1:100 consolidation on 6 Jul 2022. Authorised capital raised to 2bn shares. ISIN changed from ZAE000165239 to ZAE000309118 |
Analyst Conclusions
Management guidance and consensus
Last management guidance: the FY2024 trading statement (27 Jun 2024), which guided to a loss per share of 17.00–20.00c, and the September 2023 statement that a revised reverse-takeover transaction would be announced within four months. That transaction was never announced.
Consensus growth expectations: none. There is no analyst coverage, and the company is now unlisted.
Bull case (low-probability)
-
Re-injection of footwear assets. B&B Media owns or controls a retail-plus-manufacturing footwear chain (Socrati, Caralli, Eddels). If it chose to recapitalise Buka and inject these businesses, minorities could participate in an operating company. The AltX advisory committee's 2022 eligibility view shows the structure was once considered workable.
-
Debt-free and cheap to maintain. The shell had no debt or contingencies at FY2023. Unlisted, it no longer has to pay JSE and sponsor fees, which were R1.2–1.5m a year in FY2022–FY2023. This removes most of the cash burn and could preserve a vehicle for future use.
-
Tax-loss value. An accumulated loss above R111m may include assessed tax losses (not disclosed) that could have value in a restructuring, subject to tax law.
Bear case (high-probability)
-
No operations, no listing, near-zero equity. Equity was R1.05m in Aug 2023. The guided FY2024 loss of R2.35–2.77m implies equity of roughly zero or negative by February 2024 unless capital was injected.
-
The controlling shareholder has walked away from the transaction before. It shelved the reverse takeover in favour of its own Eddels deal, and did not contest the JSE's removal decision. Without a listing, the controlling shareholder has little incentive to inject assets into a vehicle shared with minorities.
-
Minorities' exit route has closed. The shares cannot be traded on an exchange, there are no continuing JSE disclosure obligations, and no public filings were found from September 2024 to October 2026. Liquidity and information risk for minority holders is therefore extreme.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| CIPC company status (active, deregistration, business rescue, liquidation) | Shows whether the entity continues to exist |
| Any shareholder communication from Buka or B&B Media | Any recapitalisation, buy-out offer to minorities, or asset injection |
| Filing of FY2024 and FY2025 annual financial statements (required under the Companies Act for a public company) | Confirms capital position and going concern |
| B&B Media / Socrati / Eddels corporate activity | Signals whether footwear assets are being consolidated elsewhere |
| i-BLOOM group status | Historical interest only; it holds the former Imbalie brands, but Buka has no economic interest |
Concluding analyst verdict
Buka Investments Limited is best understood as the empty legal shell left after a long, value-destroying corporate history, not as an investable company. Its operating predecessor, Imbalie Beauty, owned a credible heritage brand in Placecol and achieved premium gross margins of about 70%. It never converted that into operating profit. Revenue collapsed by about 81% between FY2016 and FY2022, from R101.1m to R19.0m. In the five audited years to FY2023 the business produced only one marginally positive EBIT year. By the time the company became a shell, it had lost roughly 98% of the R113.7m of capital ever contributed.
COVID-19 sped up an outcome that the FY2020 balance sheet was already signalling: interest cover of 0.19x, net debt about 10x EBITDA, a current ratio of 0.72x and an auditor's going-concern warning. Absa's lending condition made separating the operations from the listing unavoidable. The R7.63m related-party sale to i-BLOOM crystallised a R22.4m loss and moved every brand outside the listed perimeter.
The 2022 repositioning into fashion depended entirely on one actor: the controlling shareholder, B&B Media. When B&B Media prioritised its own Eddels acquisition, the reverse takeover stalled. The shell breached the JSE's six-month cash-shell rule, was suspended on 24 February 2023, missed its own four-month target for a revised deal, and was removed from the JSE on 4 September 2024 without appealing.
The remaining equity was being consumed mostly by directors' and listing fees and was close to nil on the FY2024 guidance. Minority shareholders now hold unlisted, illiquid shares in an entity that has made no public disclosure for more than two years. Without a voluntary recapitalisation or buy-out by the controlling shareholder, which has not been signalled, the realistic expected value for minorities is close to zero.
Verdict: no fundamental value; treat as a write-off pending any shareholder communication.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background / notes | FY2023 remuneration (ZAR K) | H1 FY2024 remuneration (ZAR K) | Source |
|---|---|---|---|---|---|---|
Abdurrahim Bux | CEO, executive director | Director from 25 Apr 2022; CEO from 1 Aug 2022 | Linked to the B&B Media consortium. Prior roles and education not disclosed in retrieved filings. Age not disclosed | 280 | 240 | FY2023 results; interim Aug 2023 |
Werner Grobbelaar | Financial Director / CFO | From 1 Aug 2022 | B.Com. Born 1971 (Yahoo Finance; Investing.com gives age 53) | 105 | 90 | FY2023 results; Yahoo Finance |
(Mohammed) Talib Sadik ("MT Sadik") | Independent non-executive chairman | From 25 Apr 2022 | Prior roles not disclosed | 220 | 146 | FY2023 results; interim Aug 2023 |
Paul Alexandre François Raoul Inbona | Independent non-executive director; chaired the Audit and Risk Committee | From 25 Apr 2022 | Prior roles not disclosed | 179 | 119 | FY2023 results |
Pumla Tladi | Independent non-executive director | From 14 Dec 2022 | Investing.com lists her as Independent Chairman, age 50. | 30 | 112 | FY2023 results; Investing.com |
Esna Colyn CA(SA) | Non-executive director (CEO until 2022); chaired the Remuneration Committee in 2022 | Director since 2010 per Investing.com; CEO through FY2022 | Chartered accountant who led Imbalie through the FY2017 restructuring, COVID and the disposal. Owns the salon company Beauty Flagship (Pty) Ltd (a related party). Later named CEO of i-BLOOM Solutions | 110 | 112 | FY2022 and FY2023 results; Team France Export |
Board of Directors — NVB Magubane
| Name | Role | Remuneration history (ZAR K) | Exit |
|---|---|---|---|
NVB Magubane | Non-executive director; chaired the Social and Ethics Committee | 92 (FY2023) | Appointed 25 Apr 2022; passed away 30 Oct 2022 |
A Cassim | Financial Director | — | 25 Apr 2022 – 31 Jul 2022 |
CW de Jager | Financial Director | 478 (FY2019), 814 (FY2020), 769 (FY2021) | Left before FY2022 |
JH Phalane | Independent chairman | 20 (FY2021), 100 (FY2022) | Resigned 25 Apr 2022 |
GD Harlow | Chaired the Nominations Committee | 80 (FY2021, FY2022) | Resigned 25 Apr 2022 |
TJ Schoeman | Chaired the Audit and Risk Committee | 80 (FY2021, FY2022) | Resigned 25 Apr 2022 |
WP van der Merwe | Chaired the Remuneration Committee | 80 (FY2021, FY2022) | Resigned 25 Apr 2022 |
BJT Shongwe | Independent chairman (2020) | 50 (FY2021) | Left by FY2022. Profile ShareData still lists him as chairman, which is stale data |
“—” = not publicly disclosed.
Directors' Remuneration
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
CEO remuneration E Colyn (ZAR K) | 966 | 945 | 981 | 1,001 |
Directors' Remuneration (FY2023–H1 FY2024)
| Metric | FY2023 | H1 FY2024 |
|---|---|---|
Executive director remuneration (ZAR K) | 385 | 330 |
Non-executive director fees (ZAR K) | 631 | 489 |
Total board cost (ZAR K) | 1,016 | 819 |
"Other operating expenses" (ZAR K) | 1,921 | 1,487 |
Governance Overview
| Feature | Detail |
|---|---|
Board size (Sep 2023) | 6 directors: 2 executive and 4 non-executive, of whom 3 independent (Sadik, Inbona, Tladi) |
Chair/CEO separation | Yes. Independent chair (Sadik), separate CEO (Bux) |
Committees (2022 disclosure) | Audit and Risk (chaired by Inbona), Social and Ethics (chaired by Magubane until her death), Remuneration (chaired by Colyn), Nominations (chaired by Harlow until his Apr 2022 resignation) |
Governance code | The company stated a commitment to King IV (interim Aug 2023) |
Gender | 2 of 6 directors were women in Sep 2023 (Colyn, Tladi), about 33% |
Major Shareholders
| Holder | Stake | Notes | Source |
|---|---|---|---|
B&B Media (Pty) Ltd | 61.26% | Acquired from previous major shareholders, effective 31 Jan 2022. Described as a fully Black-owned family business engaged mainly in advertising, with fashion and retail interests (Socrati; Eddels from Feb 2023) | FY2022 results; interim Aug 2023; Ghost Mail |
Institutional ownership | Not publicly disclosed; likely negligible given the AltX micro-cap profile | — | — |
Insider ownership | Not publicly disclosed beyond B&B Media's control stake (A Bux's link to B&B Media is implied by the board reconstitution but not quantified) | — | — |
Shares in issue | 13,840,392 ordinary no-par shares (after consolidation). Authorised: 2,000,000,000 | — | FY2023 results |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Relative positioning vs Imbalie (qualitative) |
|---|---|---|
Sorbet (salon franchise chain) | Franchised nail, beauty and skin salons | National franchise chain in direct competition for mall sites and franchisees |
Candi & Co (nail bars) | Nail services | Competes with Dream Nails and Perfect 10 for mass-market nail services |
Independent day spas and salons | Salon treatments | Fragmented and price-competitive; also an Imbalie distribution channel |
Environ (South African-founded skin care brand) | Professional skin care | Strong professional brand competing with Placecol in clinics |
Dermalogica | Professional skin care | International professional brand sold through salons |
Clicks (pharmacy and beauty retail) | Retail skin care | Both a channel and a competitor through private-label and stocked brands |
Dis-Chem (pharmacy retail) | Retail skin care | Both a channel and a competitor |
International mass and prestige skin care brands in SA retail | Retail skin care | Large marketing budgets; compete for shelf space |
Direct-selling cosmetics operators in SA | Home and direct beauty sales | Overlaps with the 2020 Customer Solutions Division model |
Online beauty retailers | E-commerce | Competes with the group's online channel |
Key Competitors — Mr Price Group
| Competitor | Overlap |
|---|---|
Mr Price Group | Mass footwear retail |
TFG (The Foschini Group) | Fashion and footwear retail |
Pepkor | Value footwear |
Edcon / Edgars (post-rescue owners) | Department-store footwear |
Specialist independent shoe chains | Directly comparable to Socrati |
Local leather shoe manufacturers | Comparable to Caralli and Eddels |
Peer Comparison FY2020
| Metric | Imbalie Beauty (FY2020, last full pre-COVID year) | Peer 1 | Peer 2 | Peer 3 |
|---|---|---|---|---|
Revenue | R33.6m | Not compiled | Not compiled | Not compiled |
Revenue growth | -19.7% | Not compiled | Not compiled | Not compiled |
Gross margin | 69.7% | Not compiled | Not compiled | Not compiled |
EBIT margin | 1.1% | Not compiled | Not compiled | Not compiled |
R&D intensity (capitalised development / revenue) | 1.7% | Not compiled | Not compiled | Not compiled |
Recent Developments
Disclosure gap. The research found no public disclosures by or about Buka Investments between 4 September 2024 (removal of listing) and 13 October 2026.*



